Introduction: Natalizumab (NTZ) is an effective drug for the treatment of relapsing-
with aggressive multiple sclerosis (MS) or poor response to the first-line therapy (Goodman et al., 2009; Miller et al., 2003; Polman et al., 2006) . However, its use has been limited due to the risk of opportunistic infections, highlighting the progressive multifocal leukoencephalopathy (PML) secondary to JC virus reactivation. PML is a demyelinating disease of the CNS with frequent fatal consequences and with an incidence of approximately 1:1,000 in the treated patients (Yousry et al., 2006) . The risk increases with longer treatment duration, the presence of anti-JCV antibodies and the prior use of immunosuppression (Fernandez et al., 2015; Yousry et al., 2006) . 638 PML cases have been reported with an incidence of 4.15/1,000 in treated patients (Biogen Idec data, March 2016, website http://www.biogenidec-international.com/tysabri.aspx?).
Therefore, in some cases, the risk is not acceptable and the discontinuation of NTZ is mandatory; the European Medicines Agency and US Food and Drug Administration have established a risk management plan, and a re-consent of all patients treated for longer than 2 years is recommended (European Medicines Agency; Fernandez et al., 2015) .
Frequently, after NTZ cessation the activity of the disease returns to pretreatment levels (Fox et al., 2014; O'Connor et al., 2011) ; however, some cases with severe clinical and radiological worsening have been described (Beume et al., 2015; Daelman et al., 2012; Gueguen et al., 2014; Jander et al., 2012; Kerbrat et al., 2011; Lenhard et al., 2010; Miravalle et al., 2011; Papeix et al., 2011; Rigau et al., 2012; Rinaldi et al., 2012; Salhofer-Polanyi et al., 2014; Sorensen et al., 2014; Vellinga et al., 2008; West & Cree, 2010) probably related to immune reconstitution inflammatory syndrome (IRIS; Lenhard et al., 2010; Miravalle et al., 2011) .
| PATIENTS AND METHODS
From a cohort of NTZ-treated patients from three hospitals in Madrid, Spain, between 2012 Spain, between -2013 ; those switched to Fingolimod (FTY) who had presented a rebound after discontinuation were reported. Clinical and magnetic resonance imaging (MRI) data were collected.
| Case report 1
A 29-year-old male was diagnosed with relapsing-remitting MS (RRMS) in 1999. He was treated with interferon beta until 2010. He started NTZ due to two relapses in previous year (no gadolinium [Gd] enhanced lesions in MRI). In February 2012 NTZ was discontinued due to the presence of 2 risk factors for PML (26 NTZ infusions and anti-JCV+). At this time, he had mild left hemiparesis and needed a cane for ambulation (Expanded Disability Status Scale [EDSS]: 6) but he was fully independent. In June 2012 FTY was started after a washout period of 3 months without adverse effects. One day later the patient was admitted to the emergency room due to drowsiness, disorientation, inattention, bradypsychia, and behavioral changes. 
| Case report 3
A 38-year-old female diagnosed with RRMS in 1999. 
| RESULTS
Four patients with a mean disease duration of 9.5 years (SD: 4.12)
were switched from NTZ to FTY due to PML risk (mean time on NTZ of 3.1 years, all patients anti-JCV+, at that time the JCV-index status was not available). The patients presented a mean of 1.5 relapses prior to NTZ therapy. FTY was started in the 3-4 following months after discontinuation. Despite the treatment, the patients presented neurological deterioration (mean: 3.5 months, SD: 2.08) with multifocal involvement: 75% presented motor disturbances, 50% cognitive impairment, and 25% seizures. Mean EDSS worsening was of 3.25 points (SD: 2.33). The MRI showed a huge increase in T2 lesions and 
| DISCUSSION
The existence of a rebound phenomenon after NTZ withdrawal is et al., 2011) . The RESTORE study, a randomized 24-week NTZ treatment interruption study, observed that up to 29% of patients after NTZ discontinuation showed an MRI disease recurrence and 15% had a clinical relapse (Fox et al., 2014) . The TY-STOP, an observational study, revealed that in the first year after NTZ cessation, up to 35% of patients had a relapse (Clerico et al., 2014) . None of these studies described a rebound phenomenon.
These differences should come from the different study settings.
The studies revised by O'Connor et al. (2011) were prior to the description of PML when NTZ was not restricted to groups of patients with more aggressive disease; Moreover, the RESTORE study, clinical (defined as a relapse the prior year) or radiological (defined as Gadolinium-enhancing lesions on screening) activity were considered exclusion criteria so only stable patients were analyzed.
The return of disease activity probably reflects an accelerated in- are few data about the neuropathological findings; in previous case reports a severe demyelinating immunopathologic pattern I lesions were described (Beume et al., 2015; Daelman et al., 2012; Lenhard et al., 2010 ) with a dense T-cell infiltrate dominated by CD8 although cases with CD4 predominance have been described (Rigau et al., 2012) indicating probably a reactivation of the disease. Thus, debate continues among neurologists as to whether some of the clinical worsening in patients after NTZ withdrawal is caused by CNS-IRIS or worsening of their MS.
The rebound rate varies among studies between 10% and 30% of patients (Gueguen et al., 2014; Havla et al., 2011; Kerbrat et al., 2011; Miravalle et al., 2011; Rinaldi et al., 2012; Salhofer-Polanyi et al., 2014; Sorensen et al., 2014; Vidal-Jordana et al., 2015) . The reactivation of the disease activity occurs frequently within the 3-6 months after NTZ cessation, in relation with the drug pharmacodynamics features (Kerbrat et al., 2011; O'Connor et al., 2011) . Cree et al. (2013) evaluated biomarkers of NTZ treatment (lymphocyte counts, alpha4-integrin saturation, sVCAM, and CD49d expression) and demonstrated that 4 months after discontinuation all the biomarkers returned to the same levels as in untreated patients.
Fast reintroduction of alternative treatment after NTZ cessation is recommended to reduce the risk of recurrence. However, there is no consensus on the appropriate management. Some studies have assessed the usefulness of different strategies, nonetheless, a bridging therapy with pulsed IV MTP or switching to disease-modifying treatment have not proved to be effective enough in controlling the disease (Havla, Keliter, & Kümpfel, 2013) . Up to 50% of patients switched to FTY, a second-line treatment for RRMS, presented a relapse, preferably during the firsts weeks (Cohen et al., 2014; Havla, Keliter, et al., 2013; Havla, Tackenberg, et al., 2013; Rinaldi et al., 2012; Vidal-Jordana et al., 2015) ; besides, rebound cases after FTY initiation have been described (Jander et al., 2012; Papeix et al., 2011) .
There are controversial data on factors predisposing to recurrence, however some studies suggest that pretreatment activity, longer MS duration (Havla, Tackenberg, et al., 2013; Lenhard et al., 2010; Miravalle et al., 2011) , increased activity in the prior months to cessation (Jokubaitis et al., 2014) and longer washout periods are the main predisposing factors. Classically, a 3-to 6-month washout period has been recommended for FTY switching (Fazekas et al., 2013; Jeffery et al., 2011) . Nevertheless, recent evidence suggests the need for shorter washout periods. O'Connor et al. (2011) pointed out that NTZ was cleared from peripheral blood by 2 months from the last infu- et al., 2011) . The TOFINGO study (Disease control and safety in RRMS patients switching from NTZ to FTY: a 32-week, rater-and patient-blind, randomized, parallel-group study) demonstrated that the 8-week over the 12-week washout group had least activity over 8 weeks of FTY treatment and over 24 weeks since the last NTZ dose, the lowest change in T2 lesion volume from baseline to week 24 and the highest proportion of patients free from Gd-enhancing lesions at week 24 (Kappos et al., 2013) . Moreover, other series supports that initiating FTY within the first 3 months is associated with a significantly lower risk of relapse (Cohen et al., 2014; Havla et al., 2011; O'Connor et al., 2011) . In our series, all the patients started FTY after 3 months, classically recommended as washout period.
There are no randomized controlled trials or established guidelines about the correct treatment in a rebound. The most frequent treatment is pulsed IV MTP for 5 days. The usefulness of PLEX is controversial with some reports of worsening maybe due to a rapid NTZ clearance in peripheral blood and an increased flux of lymphocytes into the brain (Lenhard et al., 2010) . Our patients had severe deterioration during the rebound; however, despite a mild improvement after the rebound treatment, significant disabilities (exceeding pre-NTZ treatment) were maintained over time.
| CONCLUSION
After stopping NTZ, disease activity may return to pretreatment levels or a severe rebound with a marked clinical and radiological worsening could be seen. Prior to NTZ withdraw, a risk benefit balance should be evaluated and, if cessation is mandatory, a close monitoring and an early initiation of alternative treatment are recommended after drug withdrawal.
